

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Previously Presented) A method of inhibiting angiogenesis in a subject comprising administering to the subject an agent from the group consisting of: a syndecan-4 nucleic acid molecule that can bind to cellular syndecan-4 mRNA; a syndecan-4 nucleic acid complementary to the coding strand of a double stranded cDNA molecule; and an antibody that specifically binds to a syndecan-4 protein, wherein the agent decreases syndecan-4 expression, level, or activity, in the subject.
- 2-6. (Cancelled)
7. (Previously Presented) The method of claim 1, wherein expression, level, or activity is decreased in a fibroblast or an endothelial cell.
8. (Original) The method of claim 1, wherein the subject has a disorder or condition characterized by unwanted angiogenesis or which can be treated by decreasing angiogenesis.
9. (Original) The method of claim 1, wherein the subject has a disorder characterized by unwanted cell proliferation.
10. (Original) The method of claim 1, wherein the subject has cancer.

11. (Original) The method of claim 10, wherein the cancer is characterized by the presence of a solid tumor.

12-16. (Cancelled)

17. (Previously Presented) The method of claim 1, wherein the agent is a syndecan-4 nucleic acid molecule that binds to a cellular syndecan-4 mRNA.

18. (Previously Presented) The method of claim 1, wherein the agent is a syndecan-4 nucleic acid complementary to the coding strand of a double stranded cDNA molecule.

19. (Previously Presented) The method of claim 1, wherein the agent is an antibody that specifically binds to a syndecan-4 protein.